Skip to main content

Sergio Manresa Vera

Institutions of which they are part

Research technician
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Sergio Manresa Vera

Institutions of which they are part

Research technician
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

A phase I trial of ABTL0812 in paediatric patients with advanced cancer including neuroblastoma

IP: Lucas Moreno Martín-Retortillo
Collaborators: Cristina Gamez Cenzano, Aroa Soriano Fernández, Luis Riera Soler, Miguel Segura Ginard, Carlota Aguilera Ordoñez, Sergio Manresa Vera
Funding agency: Instituto de Salud Carlos III
Funding: 826760.77
Reference: ICI21/00076
Duration: 01/01/2022 - 31/12/2025

Implementation and new biomarker development for Personalised Medicine for Childhood Cancers in Spain

IP: Lucas Moreno Martín-Retortillo
Collaborators: Aroa Soriano Fernández, Marta Garrido Pontnou, Miguel Segura Ginard, Lorena Valero Arrese, Raquel Hladun Alvaro, Elena Antima Martinez Saez, Marta Sese Faustino, Gabriela Guillén Burrieza, Josep Roma Castanyer, Andrea Vilaplana Blanes, Sergio Manresa Vera, Paula Cabre Fernandez, Margarita Ortega Blanco, María Rosario Pérez- Torres Lobato, Asbleidy Carolina Torres Barbosa
Funding agency: Instituto de Salud Carlos III
Funding: 369260
Reference: PMP21/00073
Duration: 01/01/2022 - 31/12/2025

Next generation personalised medicine for childhood cancers

IP: Lucas Moreno Martín-Retortillo
Collaborators: Aroa Soriano Fernández, Jessica Camacho Soriano, Raquel Hladun Alvaro, Gabriela Guillén Burrieza, Andrea Vilaplana Blanes, Paula Cabre Fernandez, Lorena Valero Arrese, Sergio Manresa Vera, Mariona Morell Daniel
Funding agency: Instituto de Salud Carlos III
Funding: 214170
Reference: PI21/01661
Duration: 01/01/2022 - 31/12/2024

Related news

"Generation of a bank of surgical orthotopic PDX (patient-derived xenografts) models within the framework of a personalized medicine program in pediatric cancer" was the awarded work, of the Childhood Cancer and Hematological Diseases Group of VHIR.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Related professionals

Maria Ferrer  Mateo

Maria Ferrer Mateo

Research technician
Shock, Organ Dysfunction and Resuscitation
Read more
Patricia Hinojosa Casanova

Patricia Hinojosa Casanova

Auxiliar Tècnic Recerca - Infermer/a
General Services and Infrastructures Unit
Manager
Read more
Gemma Giralt García

Gemma Giralt García

Cardiovascular Diseases
Read more
Aroa  Gomez  Brey

Aroa Gomez Brey

Research technician
Donation and transplantation of organs, tissues and cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.